857372 | VU0285655-1
N-{2-[4-oxo-1-phenyl-1,3,8-triazaspiro(4.5)decan-8-yl]ethyl}quinoline-3-carboxamide

VU0285655-1
N-{2-[4-oxo-1-phenyl-1,3,8-triazaspiro(4.5)decan-8-yl]ethyl}quinoline-3-carboxamide


CAS Registry Number is a Registered Trademark of the American Chemical Society
Lingrand M, Lalonde S, Jutras-Carignan A, Bergeron KF, Rassart E, Mounier C. SCD1 activity promotes cell migration via a PLD-mTOR pathway in the MDA-MB-231 triple-negative breast cancer cell line. Breast Cancer. 2020 Jan 29:10.1007/s12282-020-01053-8. doi: 10.1007/s12282-020-01053-8. Epub ahead of print. PMID: 31993937.
PubMed ID: 31993937Tenconi PE, Bermúdez V, Oresti GM, Giusto NM, Salvador GA, Mateos MV. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257. doi: 10.1016/j.exer.2019.04.028. Epub 2019 May 3.
PubMed ID: 31059692Wang Z, Cai M, Tay LWR, Zhang F, Wu P, Huynh A, Cao X, Di Paolo G, Peng J, Milewicz DM, Du G. Phosphatidic acid generated by PLD2 promotes the plasma membrane recruitment of IQGAP1 and neointima formation. FASEB J. 2019 Feb 27:fj201800390RR. doi: 10.1096/fj.201800390RR. [Epub ahead of print]
PubMed ID: 30811216Lavieri R, Scott SA, Lewis JA, Selvy PE, Armstrong MD, Alex Brown H, Lindsley CW. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3. doi: 10.1016/j.bmcl.2009.02.125. Epub 2009 Mar 6.
PubMed ID: 19299128- Certificate of Analysis (Lot No. 857372P-1MG-A-010 and 5829PGA010)
- Certificate of Analysis (Lot No. 857372P-1MG-B-010 and 5829PGB010)
- Certificate of Analysis (Lot No. 857372P-1MG-C-010 and 5829PGC010)
- Certificate of Analysis (Lot No. 857372P-1MG-A-011 and 5829PGA011)